Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Mississippi for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Mississippi only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Mississippi (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Muhammad Ijaz (NPI 1629490065)

Field	Value
Entity Type	Individual
Organization	Muhammad Ijaz
Address	104 Millsaps Dr
City	Hattiesburg
State	MS
ZIP	39402
Taxonomy	Rheumatology Physician
NPI Enumerated	January 18, 2014

Payer Source	Total Paid
Medicare	$1.7M
Medicaid	$0

Key Findings

This provider is effectively single‑payer: Total Medicare revenue is $1.7M while Medicaid revenue is listed as none, so the practice’s public‑payer exposure is concentrated in Medicare with no Medicaid billing on file. That payer mix suggests limited direct exposure to lower Medicaid reimbursement rates but increases dependence on Medicare and likely commercial contracts for volume and revenue stability.

Revenue is highly concentrated in a small number of infused biologic/drug codes: the precomputed top‑3 codes account for 67.7% of this provider’s total Medicare revenue. The three leading codes are J0129 ($623.9K, 35.8%), J0897 ($278.6K, 16.0%), and J9312 ($278.4K, 16.0%), indicating most Medicare dollars flow through a few specialty drug administrations rather than office E&M.

The code mix points to an infusion‑centric rheumatology practice: high revenue from J0129, J0897, J9312 and additional biologic codes such as J1602, J0717 and J1745, together with chemotherapy/infusion administration codes (96413, 96401, 96365), indicates on‑site administration of biologics and infusion therapies as a core service line. This profile is consistent with a specialty practice that generates the majority of revenue from physician‑supervised drug administration rather than procedural surgery or diagnostic imaging.

Competitive standing varies by drug: the provider is a notably high‑volume administrator of J0897, which ranks #497 of 10057 providers nationally (95th percentile) and is explicitly labeled "notably above typical national volume for this code." By contrast, J0129 (rank #162 of 1221, 87th percentile) and J9312 (rank #92 of 317, 71th percentile) are described as typical or unremarkable volumes, so market position is strongest for denosumab relative to national peers and more modest for the other leading biologics.

Office visit billing supports the infusion practice rather than driving revenue: 99214 represents 596 claims and $51.9K (3.0% of Medicare revenue) and ranks #35988 of 479517 providers nationally (92th percentile), while 99213 accounts for 311 claims and $17.4K (1.0%) and ranks at the 88th percentile. These E&M volumes indicate regular outpatient follow‑up and chronic disease management to accompany the higher‑value drug administrations.

The provider has an established enrollment history, with NPI enumerated on 2014‑01‑18 (~12 years ago), signaling roughly a decade of billing activity to build an infusion/biologics practice. That tenure aligns with the development of an infrastructure capable of supporting large volumes of physician‑administered injectable therapies.

Absence of Medicaid billing (none) creates specific contracting and access implications: the practice likely relies on Medicare and commercial payers for population access and reimbursement, which can affect payer negotiation leverage and patient referral patterns in a market where Medicaid participation is material to access for lower‑income populations. This single‑payer concentration should be considered when assessing revenue risk and payer diversification.

Ancillary procedures and in‑office services are present but represent a small share of revenue: procedural codes such as 20610 (joint injections) and lab codes like 85025 and 85651 appear on the file (with 20610 at $7.2K and 85025 at $3.2K, 85651 at $2K), consistent with point‑of‑care diagnostic monitoring and minor procedures that support ongoing rheumatology care rather than primary revenue drivers. These ancillary services complement the infusion workstream and patient management model.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

34 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	18,350	$30	$623.9K
J0897	Injection, denosumab, 1 mg	15,480	$20	$278.6K
J9312	Injection, rituximab, 10 mg	4,350	$60	$278.4K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	41,000	$1	$164K
J1602	Injection, golimumab, 1 mg, for intravenous use	13,850	$10	$138.5K
J3111	Injection, romosozumab-aqqg, 1 mg	6,930	$10	$55.4K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	600	$90	$51.9K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	1,750	$30	$45.5K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	220	$80	$18.3K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	310	$60	$17.4K

Showing 1–10 of 34

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 34 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Mississippi Distribution

Muhammad Ijaz — 1 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Mississippi

Full comparison — all codes billed, vs. state median

34 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	2	10	8,840	$30	$367.2K
J1602	7	10	18,250	$10	$265.7K
J9312	3	10	4,130	$60	$258.9K
J0717	4	10	36,000	$1	$144.1K
J3111	9	10	11,130	$10	$101.3K
J0897	7	110	3,030	$20	$95.7K
J1745	13	20	2,470	$30	$87.5K
J3304	25	30	3,090	$10	$69.4K
96413	25	70	100	$80	$22.6K
99214	589	4,110	170	$70	$21.9K

Showing 1–10 of 34

Related Providers

Other providers that share a Tax Identification Number (TIN) with Muhammad Ijaz, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Hattiesburg Clinic PA	MS	Multi-Specialty Clinic/Center	$0	$59.5M
Hattiesburg Clinic PA	MS	Pediatrics Physician	$0	$10.9M
Hattiesburg Clinic PA	MS	Pediatrics Physician	$0	$7.9M
State Of Mississippi - University Of Mississippi Medical Center	MS	Critical Access Hospital	$0	$7.5M
Hattiesburg Clinic PA	MS	Ambulatory Surgical Clinic/Center	$4.5M	$2.4M
Lowery A. Woodall Outpatient Surgery Facility, LLC	MS	Ambulatory Surgical Clinic/Center	$446.4K	$6.1M
Hattiesburg Clinic PA	MS	Clinical Medical Laboratory	$2.2M	$3.3M
Hattiesburg Clinic, PA	MS	End-Stage Renal Disease (ESRD) Treatment Clinic/Center	$0	$5.3M
Imad Bitar	MS	Rheumatology Physician	$3M	$0
Hattiesburg Clinic PA	MS	Obstetrics & Gynecology Physician	$0	$2.8M

Nearby Providers

Other providers in the same ZIP code as Muhammad Ijaz, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Wesley Health System LLC	MS	General Acute Care Hospital	$0	$37.9M
Aaa Ambulance Service	MS	Land Ambulance	$5.2M	$20.1M
Wright Lauten	MS	Retina Specialist (Ophthalmology) Physician	$11.8M	$20.3K
Middleton & Belknap Pediatric Dentistry PLLC	MS	Pediatric Dentistry	$0	$11.3M
Metro Medical Supply Company LLC	MS	Durable Medical Equipment & Medical Supplies	$0	$10.2M
Hattiesburg Road Dental, P.C.	MS	General Practice Dentistry	$0	$10.1M
Wesley Physician Services LLC	MS	Family Medicine Physician	$0	$8.2M
Latonya Hailes	MS	Community Health Worker	$0	$8M
Oral & Maxillofacial Surgery Clinic Of South Misssissippi, P.A.	MS	Oral and Maxillofacial Surgery (Dentist)	$0	$7.4M
James Harris	MS	Pediatric Dentistry	$0	$7.2M

Muhammad Ijaz — Billing Profile & Reimbursement Data

Sign up for Muhammad Ijaz — Billing Profile & Reimbursement Data policy alerts

Muhammad Ijaz — Billing Profile & Reimbursement Data

Sign up for Muhammad Ijaz — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References